To extend for two years the program for priority review to encourage treatments for rare pediatric diseases.

Section 529(b)(5) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360ff(b)(5)) is amended by striking “December 31, 2016” and inserting “December 31, 2018”.